CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Phase 1

Completed

Conditions: Clinical Pharmacology, Healthy Volunteer Study

Interventions: Drug: Pomalidomide

First Posted Date: 2013-04-19

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01835561

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions: Drug: CC-486

First Posted Date: 2013-04-19

Last Posted Date: 2018-11-20

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT01835587

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center., New York, New York, United States
🇺🇸
MD Anderson Cancer Center The University of Texas, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

and more 2 locations

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: VTX-2337
Drug: Cisplatin
Drug: Carboplatin
Drug: Placebo
Drug: 5-fluorouracil

First Posted Date: 2013-04-19

Last Posted Date: 2019-10-29

Lead Sponsor: Celgene

Target Recruit Count: 195

Registration Number: NCT01836029

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 50 locations

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Phase 3

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Oral Azacitidine
Drug: Placebo

First Posted Date: 2012-12-31

Last Posted Date: 2024-08-28

Lead Sponsor: Celgene

Target Recruit Count: 472

Registration Number: NCT01757535

Locations: 🇺🇸
Swedish Cancer Inst, Seattle, Washington, United States
🇺🇸
Local Institution - 039, San Antonio, Texas, United States
🇺🇸
Arizona Oncology Associates, P.C., Phoenix, Arizona, United States

and more 220 locations

A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid

First Posted Date: 2012-12-19

Last Posted Date: 2019-11-18

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT01752075

Locations: 🇨🇳
NTUH, Taipei, Taiwan

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia Lymphocytic Chronic B-Cell

Interventions: Drug: CC-292
Drug: Rituximab

First Posted Date: 2012-12-07

Last Posted Date: 2016-04-19

Lead Sponsor: Celgene Corporation

Target Recruit Count: 40

Registration Number: NCT01744626

Locations: 🇺🇸
Hackensack UMC, Hackensack, New Jersey, United States
🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇩🇪
Universitätsklinik Ulm, Ulm, Bayern, Germany

and more 5 locations

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2012-11-28

Last Posted Date: 2023-06-06

Lead Sponsor: Celgene

Target Recruit Count: 559

Registration Number: NCT01734928

Locations: 🇺🇸
Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States
🇺🇸
Local Institution - 132, Bangor, Maine, United States
🇺🇸
St. Agnes - Medical Center, Baltimore, Maryland, United States

and more 318 locations

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CC-220 2 mg
Drug: CC-220 0.03 mg
Drug: CC-220 0.1 mg
Drug: CC-220 0.3 mg
Drug: CC-220 1 mg
Drug: Placebo
Drug: CC-220

First Posted Date: 2012-11-27

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 65

Registration Number: NCT01733875

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Leukemia Lymphocytic Chronic B-Cell

Interventions: Drug: CC-292
Drug: Lenalidomide

First Posted Date: 2012-11-26

Last Posted Date: 2019-12-20

Lead Sponsor: Celgene

Target Recruit Count: 20

Registration Number: NCT01732861

Locations: 🇦🇹
Universitatsklinik der PMU, Salzburg, Austria
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇦🇹
Medizinische Abteilung-Zentrum fur Onkologie und Hamatologie, Wien, Austria

and more 8 locations

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Phase 2

Completed

Conditions: Adult T-Cell Leukemia-Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2012-11-09

Last Posted Date: 2018-05-29

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT01724177

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kumamoto University Hospital, Kumamoto, Japan
🇯🇵
Kagoshima University Medical and Dental Hospital, Kagoshima, Japan

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy